<DOC>
	<DOC>NCT02137616</DOC>
	<brief_summary>This study assess the safety and effects of atypical antipsychotics in subjects with psychosis syndrome and psychosis risk syndrome.</brief_summary>
	<brief_title>Antipsychotic to Treat Psychosis Syndrome</brief_title>
	<detailed_description>The investigators investigated whether administration of atypical antipsychotics could alleviate prodromal symptoms and be well tolerated by subjects with psychosis syndrome and psychosis risk syndrome.</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>were helpseeking young individuals in outpatients service aged 1630 years fitted one of the following Criteria: Psychosisrisk Syndromes (COPSSIPS) or Psychotic Syndrome (POPSSIPS) or DSMIV diagnosis of schizophreniform disorder a previous diagnosis of any psychotic disorder or bipolar disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; symptoms fully accounted for by an Axis 1 disorder or sequelae of drug/alcohol use; neurological disorders or organic disorders affecting the central nervous system, substancerelated disorders or mental retardation as defined by the DSMIV criteria; history treatment of antipsychotic or antidepression, mood stabilizers or electroconvulsive therapy; diagnosed as having a serious and unstable medical condition.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>psychosis</keyword>
	<keyword>syndrome</keyword>
	<keyword>risk</keyword>
	<keyword>antipsychotic</keyword>
</DOC>